An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists

被引：0
|
作者：
Annette Kolb-Mäurer
Cord Sunderkötter
Borries Kukowski
Sven G. Meuth
机构：
[1] Universitätsklinikum Würzburg,Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
[2] 06120 Halle (Saale) und Abteilung für translationale Dermatoinfektiologie,Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Ernst
[3] Nervenärztliche Gemeinschaftspraxis,Grube
[4] Universitätsklinikum Münster,Str. 40
[5] Albert-Schweitzer-Campus 1,Klinik für Neurologie
来源：
BMC Neurology | / 19卷
关键词：
Multiple sclerosis; Peginterferon bet-1a; Interferon beta; Flu-like symptoms; Injection site reactions; Management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE
    Newsome, Scott D.
    Kieseier, Bernd C.
    Liu, Shifang
    You, Xiaojun
    Kinter, Elizabeth
    Hung, Serena
    Sperling, Bjoern
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (01) : 41 - 50
  • [22] Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis: plegridy observational program fourth interim results
    Salvetti, M.
    Nelles, G.
    Wray, S.
    Naylor, M.
    Altincatal, A.
    Kumar, A.
    Grimes, N.
    Koster, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 552 - 553
  • [23] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Sheridan M. Hoy
    CNS Drugs, 2015, 29 : 171 - 179
  • [24] Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS
    Hersh, Carrie M.
    Fitzgerald, Kathryn
    Ryerson, Lana Zhovtis
    Mowry, Ellen
    Liao, Shirley
    Altincatal, Arman
    Naylor, Maria
    NEUROLOGY, 2021, 96 (15)
  • [25] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Hoy, Sheridan M.
    CNS DRUGS, 2015, 29 (02) : 171 - 179
  • [26] BUDGET IMPACT OF ADDING PEGINTERFERON BETA-1A TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
    Mauskopf, J. A.
    Graham, J.
    Fay-Azhar, M.
    Kinter, E.
    VALUE IN HEALTH, 2015, 18 (03) : A280 - A281
  • [27] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    VALUE IN HEALTH, 2019, 22 : S746 - S746
  • [28] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    VALUE IN HEALTH, 2019, 22 : S744 - S744
  • [29] Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA
    Klehmet, Juliane
    Begus-Nahrmann, Yvonne
    Taipale, Kirsi
    Niemczyk, Gabriele
    Rehberg-Weber, Karin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [30] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    Scott, Thomas
    Shang, Shulian
    Castrillo-Viguera, Carmen
    NEUROLOGY, 2017, 88
12345